Pfizer Inc
XHAM:PFE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Pfizer Inc
XHAM:PFE
|
US |
Intrinsic Value
The intrinsic value of 
Pfizer Inc (PFE) under the Base Case is 20.26 EUR per share.
Compared with the current market price of 27.19 EUR, the stock appears
Overvalued by 25% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Pfizer Does
Pfizer is a global drug company that discovers, develops, makes, and sells prescription medicines and vaccines. It sells treatments in areas such as vaccines, cancer, inflammation, rare diseases, internal medicine, and hospital care. Its customers are doctors, hospitals, pharmacies, governments, and health systems that buy and use its products for patients.
- Headquarters
- United States of America US
- Employees
- 75 000
- IPO date
- Jan 17, 1944
Pfizer has a narrow economic moat
Patents and exclusive rights to sell certain medicines prevent rivals from offering direct copies of important Pfizer treatments. These protections let Pfizer earn more than it could if cheaper copies were freely available, although they protect individual products rather than the entire business.
Read the full moat analysis
Revenue & Expenses Breakdown
Pfizer Inc
Earnings Waterfall
Pfizer Inc
The intrinsic value for Pfizer Inc (PFE) under the Base Case is 20.26 EUR.
Compared with the current market price of 27.19 EUR, the stock appears Overvalued by 25% .
